Want to see IMMP full AI Analyst Report?
IMMP Stock Chart & Stats
$0.38
>-$0.01(-0.08%)
At close: 4:00 PM EDT
$0.38
>-$0.01(-0.08%)
Day’s Range― - ―
52-Week Range$0.29 - $3.53
Previous CloseN/A
Volume89.72K
Average Volume (3M)123.48K
Market Cap
$48.53M
Enterprise Value$14.45
Total Cash (Recent Filing)$68.88M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Feb 25, 2027EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding147,372,130
10 Day Avg. Volume119,964
30 Day Avg. Volume123,476
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.44
Price to Sales (P/S)6.23
P/FCF Ratio-1.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.50Price Target Upside294.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$2.76M
Bulls Say, Bears Say
Bulls Say
Revenue And Licensing GrowthThe sharp revenue increase and licensing income demonstrate that Immutep can monetize its LAG-3 assets through strategic partnerships while advancing its pipeline. Although not yet product sales, these arrangements can provide milestone, collaboration, and future royalty opportunities as development progresses.
Improved Gross ProfitabilityThe return to strong gross profitability suggests a materially better revenue mix or fewer cost distortions in the latest period. If partnership-related revenue remains sustainable, this improvement could increase the contribution available to support research programs and future commercialization efforts.
Low Financial LeverageVery low leverage limits direct solvency pressure and avoids the interest burden associated with heavily debt-funded biotechnology operations. This gives Immutep greater flexibility to allocate capital toward clinical development and partnerships, even though its broader funding position remains challenging.
Bears Say
Persistent Losses And Cash BurnLarge recurring losses and negative free cash flow show that Immutep is not yet self-funding its operations. Continued clinical investment therefore requires substantial external financing or partner support, creating an ongoing risk to financial flexibility and the pace of pipeline development.
Shrinking Shareholder EquityThe substantial decline in equity indicates that sustained losses are consuming shareholder capital despite minimal debt. This weakens the financial cushion available for multi-year clinical development and may increase reliance on future capital raises, with potential dilution for existing shareholders.
Early-stage Commercialization DependenceBecause Immutep remains clinical-stage, durable product revenue depends on successful trials, regulatory progress, and eventual commercialization. Until those milestones are achieved, funding is more reliant on licensing, collaboration income, milestone payments, or capital raises than on recurring medicine sales.
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $0.29 and its highest was $3.53 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $48.53M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 25, 2027 which is in 167 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Sep 02, 2026. The company reported -$0.167 earnings per share for the quarter, missing the consensus estimate of -$0.026 by -$0.141.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.06.
How many shares outstanding does Immutep have?
Immutep has 147,372,130 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.167 in its last earnings report, missing expectations of -$0.026. Following the earnings report the stock price went up 2.965%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (294.74% Upside)
$1.50 (294.74% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
IMMP Stock 12 Month Forecast
Average Price Target
$1.50
▲(294.74% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.03% Other Institutional Investors
99.43% Public Companies and
Individual Investors